Literature DB >> 19837377

Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus.

Erin Mehlhop1, Steevenson Nelson, Christiane A Jost, Sergey Gorlatov, Syd Johnson, Daved H Fremont, Michael S Diamond, Theodore C Pierson.   

Abstract

Virus neutralization is governed by the number of antibodies that bind a virion during the cellular entry process. Cellular and serum factors that interact with antibodies have the potential to modulate neutralization potency. Although the addition of serum complement can increase the neutralizing activity of antiviral antibodies in vitro, the mechanism and significance of this augmented potency in vivo remain uncertain. Herein, we show that the complement component C1q increases the potency of antibodies against West Nile virus by modulating the stoichiometric requirements for neutralization. The addition of C1q does not result in virolysis but instead reduces the number of antibodies that must bind the virion to neutralize infectivity. For IgG subclasses that bind C1q avidly, this reduced stoichiometric threshold falls below the minimal number of antibodies required for antibody-dependent enhancement (ADE) of infection of cells expressing Fc-gamma receptors (CD32) and explains how C1q restricts the ADE of flavivirus infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19837377      PMCID: PMC2782387          DOI: 10.1016/j.chom.2009.09.003

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   21.023


  74 in total

1.  Crystal structure of west nile virus envelope glycoprotein reveals viral surface epitopes.

Authors:  Ryuta Kanai; Kalipada Kar; Karen Anthony; L Hannah Gould; Michel Ledizet; Erol Fikrig; Wayne A Marasco; Raymond A Koski; Yorgo Modis
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

2.  Enhancement of neutralizing activity of influenza virus-specific antibodies by serum components.

Authors:  Krystyna Mozdzanowska; Jingqi Feng; Mark Eid; Darya Zharikova; Walter Gerhard
Journal:  Virology       Date:  2006-06-14       Impact factor: 3.616

Review 3.  Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion.

Authors:  Melanie A Samuel; Michael S Diamond
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

4.  A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection.

Authors:  Theodore C Pierson; Melissa D Sánchez; Bridget A Puffer; Asim A Ahmed; Brian J Geiss; Laura E Valentine; Louis A Altamura; Michael S Diamond; Robert W Doms
Journal:  Virology       Date:  2005-12-02       Impact factor: 3.616

5.  West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection.

Authors:  Carl W Davis; Hai-Yen Nguyen; Sheri L Hanna; Melissa D Sánchez; Robert W Doms; Theodore C Pierson
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

6.  Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus.

Authors:  Mark Throsby; Cecile Geuijen; Jaap Goudsmit; Arjen Q Bakker; Jehanara Korimbocus; R Arjen Kramer; Marieke Clijsters-van der Horst; Maureen de Jong; Mandy Jongeneelen; Sandra Thijsse; Renate Smit; Therese J Visser; Nora Bijl; Wilfred E Marissen; Mark Loeb; David J Kelvin; Wolfgang Preiser; Jan ter Meulen; John de Kruif
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

7.  Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters.

Authors:  John D Morrey; Venkatraman Siddharthan; Aaron L Olsen; Grant Y Roper; Hong Wang; Thomas J Baldwin; Scott Koenig; Syd Johnson; Jeffrey L Nordstrom; Michael S Diamond
Journal:  J Infect Dis       Date:  2006-09-22       Impact factor: 5.226

8.  Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus.

Authors:  L Hannah Gould; Jianhua Sui; Harald Foellmer; Theodore Oliphant; Tian Wang; Michel Ledizet; Akikazu Murakami; Kristin Noonan; Cassandra Lambeth; Kalipada Kar; John F Anderson; Aravinda M de Silva; Michael S Diamond; Raymond A Koski; Wayne A Marasco; Erol Fikrig
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

9.  Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites.

Authors:  Karin Stiasny; Stefan Kiermayr; Heidemarie Holzmann; Franz X Heinz
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

10.  Protective immune responses against West Nile virus are primed by distinct complement activation pathways.

Authors:  Erin Mehlhop; Michael S Diamond
Journal:  J Exp Med       Date:  2006-05-01       Impact factor: 14.307

View more
  60 in total

1.  Complex phenotypes in mosquitoes and mice associated with neutralization escape of a Dengue virus type 1 monoclonal antibody.

Authors:  Bimmi Shrestha; S Kyle Austin; Kimberly A Dowd; Abhishek N Prasad; Soonjeon Youn; Theodore C Pierson; Daved H Fremont; Gregory D Ebel; Michael S Diamond
Journal:  Virology       Date:  2012-03-09       Impact factor: 3.616

Review 2.  Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex.

Authors:  Mario Lobigs; Michael S Diamond
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

3.  A fusion-loop antibody enhances the infectious properties of immature flavivirus particles.

Authors:  Izabela A Rodenhuis-Zybert; Bastiaan Moesker; Júlia M da Silva Voorham; Heidi van der Ende-Metselaar; Michael S Diamond; Jan Wilschut; Jolanda M Smit
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

4.  Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity.

Authors:  Stylianos Bournazos; Siu-Kei Chow; Nareen Abboud; Arturo Casadevall; Jeffrey V Ravetch
Journal:  J Clin Invest       Date:  2014-01-09       Impact factor: 14.808

Review 5.  Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity.

Authors:  Laura A VanBlargan; Leslie Goo; Theodore C Pierson
Journal:  Microbiol Mol Biol Rev       Date:  2016-10-26       Impact factor: 11.056

6.  Cross-reactive neutralizing antibodies directed against pandemic H1N1 2009 virus are protective in a highly sensitive DBA/2 mouse influenza model.

Authors:  Adrianus C M Boon; Jennifer deBeauchamp; Scott Krauss; Adam Rubrum; Ashley D Webb; Robert G Webster; Janet McElhaney; Richard J Webby
Journal:  J Virol       Date:  2010-05-19       Impact factor: 5.103

Review 7.  West Nile Virus: biology, transmission, and human infection.

Authors:  Tonya M Colpitts; Michael J Conway; Ruth R Montgomery; Erol Fikrig
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

8.  Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice.

Authors:  Matthew D Dunn; Shannan L Rossi; Donald M Carter; Matthew R Vogt; Erin Mehlhop; Michael S Diamond; Ted M Ross
Journal:  Virol J       Date:  2010-05-12       Impact factor: 4.099

9.  Impact of viral attachment factor expression on antibody-mediated neutralization of flaviviruses.

Authors:  Christopher J Obara; Kimberly A Dowd; Julie E Ledgerwood; Theodore C Pierson
Journal:  Virology       Date:  2013-01-10       Impact factor: 3.616

10.  Parainfluenza virus 5 upregulates CD55 expression to produce virions with enhanced resistance to complement-mediated neutralization.

Authors:  Yujia Li; John B Johnson; Griffith D Parks
Journal:  Virology       Date:  2016-08-06       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.